SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report: ~~October~~June 1221, ~~2011~~2012

JINZANGHUANG TIBET PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware	0-53254	26-2443288
(State of other jurisdiction of	(Commission File No.)	(IRS Employer
(State of other jurisdiction of incorporation or organization	(Commission File No.)	(IRS Employer Identification No.)
incorporation or organization		Identification No.)
Leling Economic Development Zone, Kaiyuan East Blvd., Dezhou, Shandong Province, P.R. China 253600
Harborside Financial Center, 2500 Plaza V, Jersey City, NJ 07303
(Address of principal executive offices) (Zip Code)
201-882-3332
86-534-2111-962
(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 4.0201 Change ~~Non-Reliance~~in onRegistrant’s ~~Previously~~Certifying ~~Issued Financial Statements or a Related Audit Report or Completed Interim Review~~Accountant

On ~~October~~June 1221, ~~2011~~2012 ~~Xue Bangyi,~~ the ~~Chief~~Board ~~Executive~~of ~~Officer~~Directors of ~~the~~Jinzanghuang ~~Company~~Tibet Pharmaceuticals, ~~pursuant~~Inc. approved ~~to authority granted by~~ the ~~Board~~dismissal of ~~Directors,~~De ~~concluded~~Joya ~~that~~Griffith ~~the~~& Company’s, ~~financial~~LLC ~~statements~~from ~~for~~its ~~the~~position ~~year ended June 30, 2010~~ as ~~included in~~ the ~~Company’s~~principal ~~Annual~~independent ~~Report~~accountant ~~on Form 10-K~~ for ~~the~~Jinzanghuang ~~year~~Tibet ~~ended June 30, 2010, should no longer be relied upon~~Pharmaceuticals. ~~The reasons for his conclusion were:~~

· The ~~shareholders’~~Board ~~equity~~of ~~contributed~~Directors toengaged ~~the~~De Joya Griffith & Company, LLC as aprincipal ~~result~~independent ofaccountant ~~the~~on ~~consolidation~~July 13, 2011. The audit report of ~~the~~De ~~variable~~Joya ~~interest~~Griffith ~~entity~~& Company, ~~Leling~~LLC on Jinzanghuang, ~~with~~Tibet Pharmaceutical’s financial statements for the ~~Company~~fiscal ~~had~~year ~~been~~ended ~~classified~~June as30, a2011 ~~contribution~~did ~~from~~not acontain ~~non-controlling~~an ~~interest~~adverse opinion or disclaimer of opinion or qualification or modification. De Joya Griffith & Company, ~~but~~LLC ~~should~~did ~~have~~not, ~~been~~during ~~classified~~the asapplicable periods, advise Jinzanghuang Tibet Pharmaceuticals of any of the enumerated items described in Item 304(a)(1)(iv) ~~capital~~of ~~contribution~~Regulation S-K.

·Jinzanghuang ATibet ~~contract~~Pharmaceuticals ~~deposit~~and De Joya Griffith & Company, LLC have not, during Jinzanghuang Tibet Pharmaceuticals’s most recent fiscal year or any subsequent period through the date of dismissal, had ~~been~~any ~~classified~~disagreement ason aany ~~current~~matter ~~asset~~of accounting principles or practices, ~~but~~financial ~~should~~statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to De Joya Griffith & Company, LLC’s satisfaction, would have ~~been~~caused ~~classified~~De asJoya aGriffith ~~long-term~~& ~~asset~~Company, ~~based~~LLC onto make reference to the ~~life~~subject matter of the ~~underlying~~disagreement ~~agreement~~in connection with its reports.

~~Mr.~~Jinzanghuang ~~Xue~~Tibet ~~discussed~~Pharmaceuticals ~~this~~has ~~matter~~requested ~~with~~De ~~Paritz~~Joya Griffith & Company, ~~P.A.,~~LLC ~~which~~to ~~was~~furnish ~~the~~a ~~Company’s~~letter ~~independent~~addressed ~~registered~~to ~~public~~the ~~accountant~~Securities ~~for~~Exchange ~~the~~Commission ~~year~~stating ~~ended~~whether ~~June~~or ~~30,~~not ~~2010. After~~De ~~those~~Joya ~~discussions,~~Griffith ~~the~~& Company, ~~included~~LLC aagrees ~~restatement~~with ofthe ~~its~~statements ~~financial~~in ~~statements~~this ~~for~~Form ~~the~~8-K. A ~~year~~copy ~~ended~~of ~~June~~the ~~30,~~letter ~~2010~~is infiled ~~its~~as ~~Annual~~an ~~Report~~exhibit onto ~~Form~~this 108-K ~~for the year ended June 30, 2011~~.

~~The~~On ~~effect~~June of21, 2012 Jinzanghuang Tibet Pharmaceuticals retained Stan Jeong-Ha Lee, CPA to audit Jinzanghuang Tibet Pharmaceuticals’ financial statements for the ~~restatement~~year onended June 30, 2012. At no time during the ~~balance~~two ~~sheet~~most asrecent offiscal years and the subsequent interim period through June 3021, ~~2010~~2012, isthe ~~shown~~date inof the ~~table~~engagement, ~~below~~did Jinzanghuang Tibet Pharmaceuticals consult with Stan Jeong-Ha Lee, CPA regarding any matter of the sort described above with reference to De Joya Griffith & Company, LLC, any issue relating to the financial statements of Jinzanghuang Tibet Pharmaceuticals, or the type of audit opinion that might be rendered for Jinzanghuang Tibet Pharmaceuticals.

	As Originally Reported	As Restated
Contract deposit - current portion	$ 132,570	$ 14,730
Total current assets	750,309	632,469
Contract deposit - non-current	--	117,840
Additional paid-in capital	568,077	1,264,427
Accumulated other comprehensive income	3,556	6,842
Total shareholders’ equity of the Company	484,013	1,183,649
Non-controlling interest	763,607	63,971

Item 9.01 Financial Statements and Exhibits

~~The effect of the restatement on the statement of cash flows for the year ended June 30, 2010 is shown in the table below.~~Exhibits

	As Originally Reported	As Restated
Financing activities:
Contribution from VIE	$733,000	$36,650
Capital contribution	75,380	771,730

16.1	Letter from De Joya Griffith & Company, LLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	JINZANGHUANG TIBET PHARMACEUTICALS, INC.
Dated: November 17, 2011	By:/s/ Xue Bangyi
Dated: June 26, 2012	By:/s/ Xue Bangyi
	Xue Bangyi
	Chief Executive Officer

Filing Compare · JINZANGHUANG TIBET PHARMACEUTICALS, INC.